MovDisordV3, PascalFrancis, Corpus, bibRecord, 001054

Anxiety Rating Scales in Parkinson's Disease : Critique and Recommendations

Identifieur interne : 001054 ( PascalFrancis/Corpus ); précédent : 001053; suivant : 001055

Anxiety Rating Scales in Parkinson's Disease : Critique and Recommendations

Auteurs : Albert F. G. Leentjens ; Kathy Dujardin ; Laura Marsh ; Pablo Martinez-Martin ; Irene H. Richard ; Sergio E. Starkstein ; Daniel Weintraub ; Christina Sampaio ; Werner Poewe ; Oliver Rascol ; Glenn T. Stebbins ; Christopher G. Goetz

Source :

Movement disorders [ 0885-3185 ] ; 2008.

RBID : Pascal:08-0536689

Descripteurs français

Pascal (Inist)
- Angoisse anxiété, Maladie de Parkinson, Etat dépressif, Pathologie du système nerveux, Recommandation, Psychométrie, Validité, Fiabilité.

English descriptors

KwdEn :
- Anxiety, Depression, Nervous system diseases, Parkinson disease, Psychometrics, Recommendation, Reliability, Validity.

Abstract

Anxiety syndromes are common in patients with Parkinson's disease (PD) with up to 30% suffering from panic disorder, and up to 11% from generalized anxiety disorder (GAD). Anxiety is associated with increased subjective motor symptoms, more severe gait problems, dyskinesias, freezing, and on/off fluctuations. Anxiety has a negative impact on health related quality of life and is strongly associated with depressive syndromes. Since a variety of anxiety scales have been used in PD patients, the Movement Disorder Society commissioned a task force to assess the clinimetric properties of these scales in PD. A systematic review was conducted to identify anxiety scales that have either been validated or used in patients with PD. Six anxiety rating scales were identified. These were the Beck anxiety inventory, the hospital anxiety and depression scale, the Zung self-rating anxiety scale and anxiety status inventory, the Spielberger state trait anxiety inventory, and the Hamilton anxiety rating scale. In addition, Item 5 (anxiety) of the neuropsychiatric inventory was included in the review. No scales met the criteria to be "recommended," and all scales were classified as "suggested." Essential clinimetric information is missing for all scales. Because several scales exist and have been used in PD, the task force recommends further studies of these instruments. If these studies show that the clinimetric properties of existing scales are inadequate, development of a new scale to assess anxiety in PD should be considered.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 23`
A06				`@2 14`
A08	`01`	`1`	`ENG`	`@1 Anxiety Rating Scales in Parkinson's Disease : Critique and Recommendations`
A11	`01`	`1`		`@1 LEENTJENS (Albert F. G.)`
A11	`02`	`1`		`@1 DUJARDIN (Kathy)`
A11	`03`	`1`		`@1 MARSH (Laura)`
A11	`04`	`1`		`@1 MARTINEZ-MARTIN (Pablo)`
A11	`05`	`1`		`@1 RICHARD (Irene H.)`
A11	`06`	`1`		`@1 STARKSTEIN (Sergio E.)`
A11	`07`	`1`		`@1 WEINTRAUB (Daniel)`
A11	`08`	`1`		`@1 SAMPAIO (Christina)`
A11	`09`	`1`		`@1 POEWE (Werner)`
A11	`10`	`1`		`@1 RASCOL (Oliver)`
A11	`11`	`1`		`@1 STEBBINS (Glenn T.)`
A11	`12`	`1`		`@1 GOETZ (Christopher G.)`
A14	`01`			`@1 Department of Psychiatry, Maastricht University Hospital @2 Maastricht @3 NLD @Z 1 aut.`
A14	`02`			`@1 Neurology and Movement Disorders Unit, Lille University Hospital @2 Lille @3 FRA @Z 2 aut.`
A14	`03`			`@1 Department of Psychiatry, Johns Hopkins University School of Medicine @2 Baltimore, Maryland @3 USA @Z 3 aut.`
A14	`04`			`@1 Department of Neurology, Johns Hopkins University School of Medicine @2 Baltimore, Maryland @3 USA @Z 3 aut.`
A14	`05`			`@1 Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health @2 Madrid @3 ESP @Z 4 aut.`
A14	`06`			`@1 Department of Neurology, University of Rochester School of Medicine and Dentistry @2 Rochester, New York @3 USA @Z 5 aut.`
A14	`07`			`@1 Department of Psychiatry, University of Rochester School of Medicine and Dentistry @2 Rochester, New York @3 USA @Z 5 aut.`
A14	`08`			`@1 school of Psychiatry, University of Western Australia and Fremantle Hospital @2 Fremantle, Western Australia @3 AUS @Z 6 aut.`
A14	`09`			`@1 Department of Psychiatry, University of Pennsylvania School of Medicine @2 Philadelphia, Pennsylvania @3 USA @Z 7 aut.`
A14	`10`			`@1 Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine @3 PRT @Z 8 aut.`
A14	`11`			`@1 Department of Neurology, University Hospital @2 Innsbruck @3 AUT @Z 9 aut.`
A14	`12`			`@1 Lahoratoire de Pharmacologie Medicale et Clinique @2 Toulouse @3 FRA @Z 10 aut.`
A14	`13`			`@1 Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine @2 Atlanta, Georgia @3 USA @Z 11 aut.`
A14	`14`			`@1 Department of Neurological Services, Rush University Medical Center @2 Chicago, Illinois @3 USA @Z 12 aut.`
A20				`@1 2015-2025`
A21				`@1 2008`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000184512460090`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 69 ref.`
A47	`01`	`1`		`@0 08-0536689`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Anxiety syndromes are common in patients with Parkinson's disease (PD) with up to 30% suffering from panic disorder, and up to 11% from generalized anxiety disorder (GAD). Anxiety is associated with increased subjective motor symptoms, more severe gait problems, dyskinesias, freezing, and on/off fluctuations. Anxiety has a negative impact on health related quality of life and is strongly associated with depressive syndromes. Since a variety of anxiety scales have been used in PD patients, the Movement Disorder Society commissioned a task force to assess the clinimetric properties of these scales in PD. A systematic review was conducted to identify anxiety scales that have either been validated or used in patients with PD. Six anxiety rating scales were identified. These were the Beck anxiety inventory, the hospital anxiety and depression scale, the Zung self-rating anxiety scale and anxiety status inventory, the Spielberger state trait anxiety inventory, and the Hamilton anxiety rating scale. In addition, Item 5 (anxiety) of the neuropsychiatric inventory was included in the review. No scales met the criteria to be "recommended," and all scales were classified as "suggested." Essential clinimetric information is missing for all scales. Because several scales exist and have been used in PD, the task force recommends further studies of these instruments. If these studies show that the clinimetric properties of existing scales are inadequate, development of a new scale to assess anxiety in PD should be considered.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Angoisse anxiété @5 01`
C03	`01`	`X`	`ENG`	`@0 Anxiety @5 01`
C03	`01`	`X`	`SPA`	`@0 Angustia ansiedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Etat dépressif @5 03`
C03	`03`	`X`	`ENG`	`@0 Depression @5 03`
C03	`03`	`X`	`SPA`	`@0 Estado depresivo @5 03`
C03	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 04`
C03	`04`	`X`	`ENG`	`@0 Nervous system diseases @5 04`
C03	`04`	`X`	`SPA`	`@0 Sistema nervioso patología @5 04`
C03	`05`	`X`	`FRE`	`@0 Recommandation @5 09`
C03	`05`	`X`	`ENG`	`@0 Recommendation @5 09`
C03	`05`	`X`	`SPA`	`@0 Recomendación @5 09`
C03	`06`	`X`	`FRE`	`@0 Psychométrie @5 10`
C03	`06`	`X`	`ENG`	`@0 Psychometrics @5 10`
C03	`06`	`X`	`SPA`	`@0 Psicometría @5 10`
C03	`07`	`X`	`FRE`	`@0 Validité @5 11`
C03	`07`	`X`	`ENG`	`@0 Validity @5 11`
C03	`07`	`X`	`SPA`	`@0 Validez @5 11`
C03	`08`	`X`	`FRE`	`@0 Fiabilité @5 12`
C03	`08`	`X`	`ENG`	`@0 Reliability @5 12`
C03	`08`	`X`	`SPA`	`@0 Fiabilidad @5 12`
C07	`01`	`X`	`FRE`	`@0 Affect affectivité @5 37`
C07	`01`	`X`	`ENG`	`@0 Affect affectivity @5 37`
C07	`01`	`X`	`SPA`	`@0 Afecto afectividad @5 37`
C07	`02`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 38`
C07	`02`	`X`	`ENG`	`@0 Cerebral disorder @5 38`
C07	`02`	`X`	`SPA`	`@0 Encéfalo patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 39`
C07	`03`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 39`
C07	`03`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 39`
C07	`04`	`X`	`FRE`	`@0 Maladie dégénérative @5 40`
C07	`04`	`X`	`ENG`	`@0 Degenerative disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 40`
C07	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 41`
C07	`05`	`X`	`ENG`	`@0 Central nervous system disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 41`
C07	`06`	`X`	`FRE`	`@0 Trouble de l'humeur @5 43`
C07	`06`	`X`	`ENG`	`@0 Mood disorder @5 43`
C07	`06`	`X`	`SPA`	`@0 Trastorno humor @5 43`
N21				`@1 350`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 08-0536689 INIST
ET :	Anxiety Rating Scales in Parkinson's Disease : Critique and Recommendations
AU :	LEENTJENS (Albert F. G.); DUJARDIN (Kathy); MARSH (Laura); MARTINEZ-MARTIN (Pablo); RICHARD (Irene H.); STARKSTEIN (Sergio E.); WEINTRAUB (Daniel); SAMPAIO (Christina); POEWE (Werner); RASCOL (Oliver); STEBBINS (Glenn T.); GOETZ (Christopher G.)
AF :	Department of Psychiatry, Maastricht University Hospital/Maastricht/Pays-Bas (1 aut.); Neurology and Movement Disorders Unit, Lille University Hospital/Lille/France (2 aut.); Department of Psychiatry, Johns Hopkins University School of Medicine/Baltimore, Maryland/Etats-Unis (3 aut.); Department of Neurology, Johns Hopkins University School of Medicine/Baltimore, Maryland/Etats-Unis (3 aut.); Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health/Madrid/Espagne (4 aut.); Department of Neurology, University of Rochester School of Medicine and Dentistry/Rochester, New York/Etats-Unis (5 aut.); Department of Psychiatry, University of Rochester School of Medicine and Dentistry/Rochester, New York/Etats-Unis (5 aut.); school of Psychiatry, University of Western Australia and Fremantle Hospital/Fremantle, Western Australia/Australie (6 aut.); Department of Psychiatry, University of Pennsylvania School of Medicine/Philadelphia, Pennsylvania/Etats-Unis (7 aut.); Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine/Portugal (8 aut.); Department of Neurology, University Hospital/Innsbruck/Autriche (9 aut.); Lahoratoire de Pharmacologie Medicale et Clinique/Toulouse/France (10 aut.); Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine/Atlanta, Georgia/Etats-Unis (11 aut.); Department of Neurological Services, Rush University Medical Center/Chicago, Illinois/Etats-Unis (12 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2008; Vol. 23; No. 14; Pp. 2015-2025; Bibl. 69 ref.
LA :	Anglais
EA :	Anxiety syndromes are common in patients with Parkinson's disease (PD) with up to 30% suffering from panic disorder, and up to 11% from generalized anxiety disorder (GAD). Anxiety is associated with increased subjective motor symptoms, more severe gait problems, dyskinesias, freezing, and on/off fluctuations. Anxiety has a negative impact on health related quality of life and is strongly associated with depressive syndromes. Since a variety of anxiety scales have been used in PD patients, the Movement Disorder Society commissioned a task force to assess the clinimetric properties of these scales in PD. A systematic review was conducted to identify anxiety scales that have either been validated or used in patients with PD. Six anxiety rating scales were identified. These were the Beck anxiety inventory, the hospital anxiety and depression scale, the Zung self-rating anxiety scale and anxiety status inventory, the Spielberger state trait anxiety inventory, and the Hamilton anxiety rating scale. In addition, Item 5 (anxiety) of the neuropsychiatric inventory was included in the review. No scales met the criteria to be "recommended," and all scales were classified as "suggested." Essential clinimetric information is missing for all scales. Because several scales exist and have been used in PD, the task force recommends further studies of these instruments. If these studies show that the clinimetric properties of existing scales are inadequate, development of a new scale to assess anxiety in PD should be considered.
CC :	002B17; 002B17G
FD :	Angoisse anxiété; Maladie de Parkinson; Etat dépressif; Pathologie du système nerveux; Recommandation; Psychométrie; Validité; Fiabilité
FG :	Affect affectivité; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central; Trouble de l'humeur
ED :	Anxiety; Parkinson disease; Depression; Nervous system diseases; Recommendation; Psychometrics; Validity; Reliability
EG :	Affect affectivity; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Mood disorder
SD :	Angustia ansiedad; Parkinson enfermedad; Estado depresivo; Sistema nervioso patología; Recomendación; Psicometría; Validez; Fiabilidad
LO :	INIST-20953.354000184512460090
ID :	08-0536689

Links to Exploration step

Pascal:08-0536689

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Anxiety Rating Scales in Parkinson's Disease : Critique and Recommendations</title>
<author><name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, Maastricht University Hospital</s1>
<s2>Maastricht</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name>
<affiliation><inist:fA14 i1="02"><s1>Neurology and Movement Disorders Unit, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Psychiatry, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation><inist:fA14 i1="05"><s1>Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="07"><s1>Department of Psychiatry, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Starkstein, Sergio E" sort="Starkstein, Sergio E" uniqKey="Starkstein S" first="Sergio E." last="Starkstein">Sergio E. Starkstein</name>
<affiliation><inist:fA14 i1="08"><s1>school of Psychiatry, University of Western Australia and Fremantle Hospital</s1>
<s2>Fremantle, Western Australia</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
<affiliation><inist:fA14 i1="09"><s1>Department of Psychiatry, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sampaio, Christina" sort="Sampaio, Christina" uniqKey="Sampaio C" first="Christina" last="Sampaio">Christina Sampaio</name>
<affiliation><inist:fA14 i1="10"><s1>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine</s1>
<s3>PRT</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation><inist:fA14 i1="11"><s1>Department of Neurology, University Hospital</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Oliver Rascol</name>
<affiliation><inist:fA14 i1="12"><s1>Lahoratoire de Pharmacologie Medicale et Clinique</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name>
<affiliation><inist:fA14 i1="13"><s1>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation><inist:fA14 i1="14"><s1>Department of Neurological Services, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0536689</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0536689 INIST</idno>
<idno type="RBID">Pascal:08-0536689</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001054</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Anxiety Rating Scales in Parkinson's Disease : Critique and Recommendations</title>
<author><name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, Maastricht University Hospital</s1>
<s2>Maastricht</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name>
<affiliation><inist:fA14 i1="02"><s1>Neurology and Movement Disorders Unit, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Psychiatry, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation><inist:fA14 i1="05"><s1>Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="07"><s1>Department of Psychiatry, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Starkstein, Sergio E" sort="Starkstein, Sergio E" uniqKey="Starkstein S" first="Sergio E." last="Starkstein">Sergio E. Starkstein</name>
<affiliation><inist:fA14 i1="08"><s1>school of Psychiatry, University of Western Australia and Fremantle Hospital</s1>
<s2>Fremantle, Western Australia</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
<affiliation><inist:fA14 i1="09"><s1>Department of Psychiatry, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sampaio, Christina" sort="Sampaio, Christina" uniqKey="Sampaio C" first="Christina" last="Sampaio">Christina Sampaio</name>
<affiliation><inist:fA14 i1="10"><s1>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine</s1>
<s3>PRT</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation><inist:fA14 i1="11"><s1>Department of Neurology, University Hospital</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Oliver Rascol</name>
<affiliation><inist:fA14 i1="12"><s1>Lahoratoire de Pharmacologie Medicale et Clinique</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name>
<affiliation><inist:fA14 i1="13"><s1>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation><inist:fA14 i1="14"><s1>Department of Neurological Services, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anxiety</term>
<term>Depression</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Psychometrics</term>
<term>Recommendation</term>
<term>Reliability</term>
<term>Validity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Angoisse anxiété</term>
<term>Maladie de Parkinson</term>
<term>Etat dépressif</term>
<term>Pathologie du   système nerveux</term>
<term>Recommandation</term>
<term>Psychométrie</term>
<term>Validité</term>
<term>Fiabilité</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Anxiety syndromes are common in patients with Parkinson's disease (PD) with up to 30% suffering from panic disorder, and up to 11% from generalized anxiety disorder (GAD). Anxiety is associated with increased subjective motor symptoms, more severe gait problems, dyskinesias, freezing, and on/off fluctuations. Anxiety has a negative impact on health related quality of life and is strongly associated with depressive syndromes. Since a variety of anxiety scales have been used in PD patients, the Movement Disorder Society commissioned a task force to assess the clinimetric properties of these scales in PD. A systematic review was conducted to identify anxiety scales that have either been validated or used in patients with PD. Six anxiety rating scales were identified. These were the Beck anxiety inventory, the hospital anxiety and depression scale, the Zung self-rating anxiety scale and anxiety status inventory, the Spielberger state trait anxiety inventory, and the Hamilton anxiety rating scale. In addition, Item 5 (anxiety) of the neuropsychiatric inventory was included in the review. No scales met the criteria to be "recommended," and all scales were classified as "suggested." Essential clinimetric information is missing for all scales. Because several scales exist and have been used in PD, the task force recommends further studies of these instruments. If these studies show that the clinimetric properties of existing scales are inadequate, development of a new scale to assess anxiety in PD should be considered.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>23</s2>
</fA05>
<fA06><s2>14</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Anxiety Rating Scales in Parkinson's Disease : Critique and Recommendations</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>LEENTJENS (Albert F. G.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>DUJARDIN (Kathy)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MARSH (Laura)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>MARTINEZ-MARTIN (Pablo)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>RICHARD (Irene H.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>STARKSTEIN (Sergio E.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>WEINTRAUB (Daniel)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>SAMPAIO (Christina)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>POEWE (Werner)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>RASCOL (Oliver)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>STEBBINS (Glenn T.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>GOETZ (Christopher G.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Psychiatry, Maastricht University Hospital</s1>
<s2>Maastricht</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Neurology and Movement Disorders Unit, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Psychiatry, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neurology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Psychiatry, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>school of Psychiatry, University of Western Australia and Fremantle Hospital</s1>
<s2>Fremantle, Western Australia</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Department of Psychiatry, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine</s1>
<s3>PRT</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Department of Neurology, University Hospital</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Lahoratoire de Pharmacologie Medicale et Clinique</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="13"><s1>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="14"><s1>Department of Neurological Services, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA20><s1>2015-2025</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000184512460090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>69 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0536689</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Anxiety syndromes are common in patients with Parkinson's disease (PD) with up to 30% suffering from panic disorder, and up to 11% from generalized anxiety disorder (GAD). Anxiety is associated with increased subjective motor symptoms, more severe gait problems, dyskinesias, freezing, and on/off fluctuations. Anxiety has a negative impact on health related quality of life and is strongly associated with depressive syndromes. Since a variety of anxiety scales have been used in PD patients, the Movement Disorder Society commissioned a task force to assess the clinimetric properties of these scales in PD. A systematic review was conducted to identify anxiety scales that have either been validated or used in patients with PD. Six anxiety rating scales were identified. These were the Beck anxiety inventory, the hospital anxiety and depression scale, the Zung self-rating anxiety scale and anxiety status inventory, the Spielberger state trait anxiety inventory, and the Hamilton anxiety rating scale. In addition, Item 5 (anxiety) of the neuropsychiatric inventory was included in the review. No scales met the criteria to be "recommended," and all scales were classified as "suggested." Essential clinimetric information is missing for all scales. Because several scales exist and have been used in PD, the task force recommends further studies of these instruments. If these studies show that the clinimetric properties of existing scales are inadequate, development of a new scale to assess anxiety in PD should be considered.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Angoisse anxiété</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Anxiety</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Angustia ansiedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Etat dépressif</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Depression</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Estado depresivo</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Recommandation</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Recommendation</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Recomendación</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Psychométrie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Psychometrics</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Psicometría</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Validité</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Validity</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Validez</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Fiabilité</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Reliability</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Fiabilidad</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Affect affectivité</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Affect affectivity</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Afecto afectividad</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Trouble de l'humeur</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Mood disorder</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Trastorno humor</s0>
<s5>43</s5>
</fC07>
<fN21><s1>350</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 08-0536689 INIST</NO>
<ET>Anxiety Rating Scales in Parkinson's Disease : Critique and Recommendations</ET>
<AU>LEENTJENS (Albert F. G.); DUJARDIN (Kathy); MARSH (Laura); MARTINEZ-MARTIN (Pablo); RICHARD (Irene H.); STARKSTEIN (Sergio E.); WEINTRAUB (Daniel); SAMPAIO (Christina); POEWE (Werner); RASCOL (Oliver); STEBBINS (Glenn T.); GOETZ (Christopher G.)</AU>
<AF>Department of Psychiatry, Maastricht University Hospital/Maastricht/Pays-Bas (1 aut.); Neurology and Movement Disorders Unit, Lille University Hospital/Lille/France (2 aut.); Department of Psychiatry, Johns Hopkins University School of Medicine/Baltimore, Maryland/Etats-Unis (3 aut.); Department of Neurology, Johns Hopkins University School of Medicine/Baltimore, Maryland/Etats-Unis (3 aut.); Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health/Madrid/Espagne (4 aut.); Department of Neurology, University of Rochester School of Medicine and Dentistry/Rochester, New York/Etats-Unis (5 aut.); Department of Psychiatry, University of Rochester School of Medicine and Dentistry/Rochester, New York/Etats-Unis (5 aut.); school of Psychiatry, University of Western Australia and Fremantle Hospital/Fremantle, Western Australia/Australie (6 aut.); Department of Psychiatry, University of Pennsylvania School of Medicine/Philadelphia, Pennsylvania/Etats-Unis (7 aut.); Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine/Portugal (8 aut.); Department of Neurology, University Hospital/Innsbruck/Autriche (9 aut.); Lahoratoire de Pharmacologie Medicale et Clinique/Toulouse/France (10 aut.); Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine/Atlanta, Georgia/Etats-Unis (11 aut.); Department of Neurological Services, Rush University Medical Center/Chicago, Illinois/Etats-Unis (12 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2008; Vol. 23; No. 14; Pp. 2015-2025; Bibl. 69 ref.</SO>
<LA>Anglais</LA>
<EA>Anxiety syndromes are common in patients with Parkinson's disease (PD) with up to 30% suffering from panic disorder, and up to 11% from generalized anxiety disorder (GAD). Anxiety is associated with increased subjective motor symptoms, more severe gait problems, dyskinesias, freezing, and on/off fluctuations. Anxiety has a negative impact on health related quality of life and is strongly associated with depressive syndromes. Since a variety of anxiety scales have been used in PD patients, the Movement Disorder Society commissioned a task force to assess the clinimetric properties of these scales in PD. A systematic review was conducted to identify anxiety scales that have either been validated or used in patients with PD. Six anxiety rating scales were identified. These were the Beck anxiety inventory, the hospital anxiety and depression scale, the Zung self-rating anxiety scale and anxiety status inventory, the Spielberger state trait anxiety inventory, and the Hamilton anxiety rating scale. In addition, Item 5 (anxiety) of the neuropsychiatric inventory was included in the review. No scales met the criteria to be "recommended," and all scales were classified as "suggested." Essential clinimetric information is missing for all scales. Because several scales exist and have been used in PD, the task force recommends further studies of these instruments. If these studies show that the clinimetric properties of existing scales are inadequate, development of a new scale to assess anxiety in PD should be considered.</EA>
<CC>002B17; 002B17G</CC>
<FD>Angoisse anxiété; Maladie de Parkinson; Etat dépressif; Pathologie du   système nerveux; Recommandation; Psychométrie; Validité; Fiabilité</FD>
<FG>Affect affectivité; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central; Trouble de l'humeur</FG>
<ED>Anxiety; Parkinson disease; Depression; Nervous system diseases; Recommendation; Psychometrics; Validity; Reliability</ED>
<EG>Affect affectivity; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Mood disorder</EG>
<SD>Angustia ansiedad; Parkinson enfermedad; Estado depresivo; Sistema nervioso patología; Recomendación; Psicometría; Validez; Fiabilidad</SD>
<LO>INIST-20953.354000184512460090</LO>
<ID>08-0536689</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001054 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001054 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:08-0536689
   |texte=   Anxiety Rating Scales in Parkinson's Disease : Critique and Recommendations
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Anxiety Rating Scales in Parkinson's Disease : Critique and Recommendations

Anxiety Rating Scales in Parkinson's Disease : Critique and Recommendations

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri